Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 4, 2010, Pages 934-941

  de Bruijn, Peter ^a   Sleijfer, Stefan ^a   Lam, Mei Ho ^a   Mathijssen, Ron H J ^a   Wiemer, Erik A C ^a   Loos, Walter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Human plasma; Light sensitivity; SU12662; Sunitinib; UPLC MS MS

Indexed keywords

ACETONITRILE; DESETHYLSUNITINIB; DRUG METABOLITE; EDETIC ACID; SU 12662; SUNITINIB; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; ELUTION; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ADULT; ANGIOGENESIS INHIBITORS; BIOTRANSFORMATION; CALIBRATION; CHROMATOGRAPHY, LIQUID; DEALKYLATION; FEMALE; HUMANS; INDOLES; PYRROLES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 72149128890     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.10.020     Document Type: Article

References (16)

1. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., and Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24 (2006) 25-35
2. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher C.D., George S., Bello C.L., Huang X., Baum C.M., and Casali P.G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
3. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., and Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 115-124
4. Demetri G.D., Wang Y., Wehrle E., Racine A., Nikolova Z., Blanke C.D., Joensuu H., and von Mehren M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J. Clin. Oncol. 27 (2009) 3141-3147
5. B.E. Houk, C.L. Bello, M.D. Michaelson, R.M. Bukowski, B.G. Redman, G.R. Hudes, G. Wilding, R.J. Motzer, Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach, J. Clin. Oncol., 2007 ASCO Annual Meeting Proceedings Part I, vol. 25, no. 18S, abstract 5027 (June 20 Suppl.), 2007.
6. van Erp N.P., Eechoute K., van der Veldt A.A., Haanen J.B., Reyners A.K., Mathijssen R.H., Boven E., van der Straaten T., Baak-Pablo R.F., Wessels J.A., Guchelaar H.J., and Gelderblom H. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol. 27 (2009) 4406-4412
7. Bello C.L., Sherman L., Zhou J., Verkh L., Smeraglia J., Mount J., and Klamerus K.J. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17 (2006) 353-358
8. Britten C.D., Kabbinavar F., Hecht J.R., Bello C.L., Li J., Baum C., and Slamon D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. 61 (2008) 515-524
9. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O.G., O'Farrell A.M., Bello C.L., Allred R., Manning W.C., Cherrington J.M., Louie S.G., Hong W., Brega N.M., Massimini G., Scigalla P., Berdel W.E., and Hossfeld D.K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
10. Haznedar J.O., Patyna S., Bello C.L., Peng G.W., Speed W., Yu X., Zhang Q., Sukbuntherng J., Sweeny D.J., Antonian L., and Wu E.Y. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother. Pharmacol. 64 (2009) 691-706
11. Minkin P., Zhao M., Chen Z., Ouwerkerk J., Gelderblom H., and Baker S.D. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 874 (2008) 84-88
12. Zhao Y., Sukbuntherng J., and Antonian L. Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS. J. Pharm. Biomed. Anal. 35 (2004) 513-522
13. de Bruijn P., Moghaddam-Helmantel I.M., de Jonge M.J., Meyer T., Lam M.H., Verweij J., Wiemer E.A., and Loos W.J. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 50 (2009) 977-982
14. Rosing H., Man W.Y., Doyle E., Bult A., and Beijnen J.H. Bioanalytical liquid chromatographic method validation. A review of current practices and procedures. J. Liq. Chromatogr. Rel. Technol. 23 (2000) 329-354
15. Brain E.G., Rezai K., Weill S., Gauzan M.F., Santoni J., Besse B., Goupil A., Turpin F., Urien S., and Lokiec F. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study. Cancer Chemother. Pharmacol. 60 (2007) 375-381
16. Coriat R., Mir O., Camps S., Ropert S., Billemont B., Leconte M., Larousserie F., Anract P., Alexandre J., and Goldwasser F. Ambulatory administration of 5-day infusion ifosfamide + mesna: a pilot study in sarcoma patients. Cancer Chemother. Pharmacol. (2009) (Epub ahead of print)